Published in Clin Pharmacol Ther on June 01, 2001
Pulmonary Tuberculosis Patients With Diabetes Mellitus (TANDEM) | NCT02106039
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg (2009) 2.30
The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis (2011) 1.17
Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther (2008) 1.14
The transcriptional regulation of the human CYP2C genes. Curr Drug Metab (2009) 1.07
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol (2009) 1.02
Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol (2014) 1.00
Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol (2006) 0.95
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol (2007) 0.94
Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos (2010) 0.94
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol (2014) 0.91
Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012. Ann Epidemiol (2014) 0.87
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br J Clin Pharmacol (2003) 0.85
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol (2005) 0.83
Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol (2008) 0.83
Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. Mol Pharmacol (2014) 0.80
Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cells. J Pharmacol Exp Ther (2013) 0.80
Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity. J Pharm Pharm Sci (2011) 0.79
Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J (2014) 0.76
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (1998) 2.09
Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol (1983) 2.09
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (1998) 1.99
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet (1983) 1.89
Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol (1979) 1.82
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet (1993) 1.70
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol (1978) 1.62
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther (1997) 1.59
Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation: comparison between propofol and thiopentone. Br J Anaesth (1993) 1.54
Local infiltration analgesia with levobupivacaine compared with intrathecal morphine in total hip arthroplasty patients. Acta Anaesthesiol Scand (2012) 1.53
Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol (1985) 1.50
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 1.49
A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther (1993) 1.45
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 1.42
Cyclosporine A increases plasma concentrations and effects of repaglinide. Am J Transplant (2006) 1.40
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther (2001) 1.40
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol (1980) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 1.34
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 1.32
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg (1996) 1.31
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 1.30
Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol (1978) 1.29
Interactions with the absorption of tetracyclines. Drugs (1976) 1.29
Sotalol and prolonged Q-Tc interval. Lancet (1981) 1.27
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia (2003) 1.27
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum (1998) 1.26
Interference of iron with the absorption of tetracyclines in man. Br Med J (1970) 1.25
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 1.24
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol (1998) 1.24
Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology (2007) 1.22
Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol (2002) 1.22
Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol (1985) 1.22
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias. Eur Heart J (1981) 1.20
Drug-related deaths in a university central hospital. Eur J Clin Pharmacol (2002) 1.18
The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG (2000) 1.17
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther (2007) 1.16
Itraconazole decreases renal clearance of digoxin. Ther Drug Monit (1997) 1.16
Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther (1998) 1.13
Inhibitory effect of various iron salts on the absorption of tetracycline in man. Eur J Clin Pharmacol (1974) 1.11
Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol (1994) 1.11
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol (2001) 1.08
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia (2003) 1.06
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother (2001) 1.05
Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J (1979) 1.05
Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol (1981) 1.05
Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother (1992) 1.04
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos (2000) 1.04
Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneimittelforschung (1975) 1.04
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos (2001) 1.04
Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2000) 1.04
Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol (1979) 1.03
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (2000) 1.03
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther (2006) 1.02
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2001) 1.00
The clinical significance of food-drug interactions: a review. Med J Aust (1989) 1.00
Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol (1992) 1.00
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther (1995) 0.99
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol (1997) 0.99
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol (1980) 0.99
Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man. Eur J Clin Pharmacol (1975) 0.98